Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial

Journal of the National Cancer Institute

Volumn 104, Issue 16, 2012, Pages 1264-

  Nakamura, Yusuke ^a   Ratain, Mark J ^a   Cox, Nancy J ^a   McLeod, Howard L ^b   Kroetz, Deanna L ^c   Flockhart, David A ^d  

^a University of Chicago   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DNA; TAMOXIFEN;

BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENOTYPE; HORMONE RELEASE; HUMAN; LETTER; POSTMENOPAUSE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NITRILES; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 84865486320     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs304     Document Type: Letter

References (7)

1. R egan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst. 2012;104(6):441-451.
2. R ae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452-460.
3. Kelly CM, Pritchard KI. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J Natl Cancer Inst. 2012;104(6):427-428.
4. Fleeman N, Martin Saborido C, Payne K, et al. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess. 2011;15(33):1-102.
5. Gomes I, Collins A, Lonjou C, et al. Hardy-Weinberg quality control. Ann Hum Genet. 1999;63(6):535-538. (Pubitemid 30171082)
6. Castells A, Gusella JF, Ramesh V, et al. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res. 2000;60(11):2836-2839. (Pubitemid 30395802)
7. H irano A, Emi M, Tsuneizumi M, et al. Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res. 2001;7(4):876-882. (Pubitemid 32708724)